Feellife® Three-piece set for the prevention of pulmonary nodules of diagnosis and treatment

In recent years, the detection rate of pulmonary nodule lesions has increased significantly. Clinically, lesions within the lung parenchyma that are less than or equal to 3 cm (excluding atelectasis and enlarged lymph nodes) are called nodules, lesions larger than 3 cm are called masses, and nodules smaller than 1 cm are called small nodules, and those smaller than 5 mm are called micronodules. The reason for this definition is that lesions larger than 3 cm are mostly malignant, while smaller lesions may be benign or malignant. There is a correlation between the size of the nodule and the benign or malignant nature of the nodule. Small nodules are more likely to be benign.


There are several types of people who should not take it lightly when they find small lung nodules during physical examinations. They should actively receive formal further examinations and timely treatment:

(1) People who have smoked for more than 20 years, smoke more than 20 cigarettes a day, or have been exposed to passive smoking for a long time;

(2) People who are over 40 years old and have symptoms such as chest pain, cough, unexplained blood in sputum, emaciation, weight loss, etc.;

(3) People with a family history of tumors, especially a family history of lung cancer;

(4) Nodules larger than 1 cm in size, accompanied by changes such as spicule-like, lobed or ground-glass-like, and pleural indentation.

Feellife® Three-piece set for the prevention of pulmonary nodules of diagnosis and treatment

In chest CT examination, nodules smaller than 5 mm are too small to have obvious characteristics of benign or malignant, and various examinations are difficult to determine their nature. More than half of single small nodules in the lungs with a diameter greater than 1 cm are malignant, while more than 90% of tiny nodules smaller than 5 mm are benign. Therefore, lung nodules smaller than 5 mm can be reexamined by CT every 6 months; lung nodules of 5-10 mm should be reexamined by CT every 3 months; and lung nodules of 10 mm should be reexamined by CT every 1 to 2 months. If the follow-up finds no change in the lesion, the reexamination is often extended to 3-6 months or 1 year. If a small lung nodule is found to have no change for 2 years, it can be generally considered a benign nodule. When changes are found in the lesion, the next step of treatment is determined based on the changes.


The Fleischner Society Guidelines (2017) recommend the selection of 6 mm (100 mm3) as the main cutoff value for shortening the follow-up interval. For multiple solid nodules, if the size is<6 mm (100 mm3), if classified as high risk, follow-up is recommended at 12 months, otherwise no routine follow-up is required; for those with the main lesion ≥6 mm (100 mm3), follow-up is recommended for 3 to 6 months, and a second follow-up is selectively performed at 18 to 24 months. For multiple subsolid nodules, follow-up for 3 to 6 months is recommended, and subsequent treatment is determined based on the most suspicious nodule. Among them, multiple pGGNs <6 mm are mostly benign, but high-risk patients are recommended to be followed up in the second and fourth years.

Early testing, early intervention, and early treatment effectively improve our understanding of lung conditions.


With the vision of "providing a third way of dosing", Feellife® focuses on the field of medical nebulization and respiratory health. With its strong scientific research capabilities and deep insight into user demands, it has devoted itself to the research and development of more than 220 atomization patents with AiMesh® as the core for more than ten years, and has pioneered the development of intelligent variable frequency atomization technology, quantitative atomization technology, and respiratory sensing atomization technology, all of which have been successfully applied to atomizers. Through the business model of "intelligent nebulizer + nebulization liquid", it provides atomization solutions to the world and serves the global atomization ecosystem.


At the same time, feellife's pulmonary function testing equipment obtained FDA certification in 2023, adding luster to the creation of a closed loop of respiratory and lung health prevention, treatment and rehabilitation.


We have launched a "three-piece set of tuberculosis rehabilitation" treatment plan, including the Air Smart TT lung function test, the fit series of lung training, and the Airbar Pro 1 oxygen concentrator. For home use, you can choose a more compact and portable portable respiratory measurement device. With one blow every day, you can monitor your health in real time. The mobile phone APP generates health data, and trend changes are clear at a glance.

Feellife® Three-piece set for the prevention of pulmonary nodules of diagnosis and treatment

In addition, you can perform lung function training every day. Try the portable Airfit1 at home to train your respiratory muscles, increase your respiratory and cardiopulmonary functions, make it easier to breathe during exercise, and make lung exercise easier.

Feellife® Three-piece set for the prevention of pulmonary nodules of diagnosis and treatment

As a home oxygen concentrator, the main function of Airbar Pro 1 is to provide users with pure medical oxygen, improve symptoms such as dyspnea and hypoxia, and improve the quality of life. At the same time, the oxygen content can be as high as 93%.

Feellife® Three-piece set for the prevention of pulmonary nodules of diagnosis and treatment

Effects of budesonide nebulization

Nebulization of budesonide is a common way of administering medicine. It can make the medicine reach the symptomatic site to the greatest extent, and is especially suitable for children. For babies, this type of medicine can also be used for treatment. It is very effective in preventing cough and treating bronchitis. During the process of nebulization treatment, it is also necessary to take the medicine orally as prescribed by the doctor.


The efficacy of budesonide nebulization on babies.

Since atomization itself is only a method of drug administration, a special atomization device is used to atomize the drug solution into tiny particles, which are inhaled into the respiratory tract and lungs to deposit the drug in the respiratory tract to treat diseases. Compared with the traditional injection and medication, small particles are The baby does not suffer much pain. This treatment method is administered in small doses and effectively reduces side effects.

Effects of budesonide nebulization

Budesonide suspension is the most commonly used aerosolized drug in clinical practice. The drug mechanism is that ICS surface inhaled hormones. Everyone gets nervous when they hear about hormones, thinking that the doctor is going to give me hormones again. They are anxious about whether I will gain weight or my blood sugar will increase if I use hormones.

In fact, budesonide suspension is a surface inhaled hormone. Its main function is to control inflammation through atomization, reduce inflammatory cells, reduce the ability to secrete mucus, and reduce the level of secreted mucus and inflammatory factors. In short, it can clear the airway, inhibit airway inflammation, and play a role in dilating the airway through local deposition in the airway, so not many components enter the blood. This kind of local atomization causes patients to react to hormones, including increased blood sugar and obesity, and these side effects are very small.

Effects of budesonide nebulization

Local use of hormones has such a rapid onset, which can relieve spasms and asthma, and at the same time will not cause changes in the blood sugar level of the whole body. Therefore, in patients with COPD, patients with bronchial asthma, and cough variant asthma, these clinical symptoms appear, surface inhaled hormones and inhaled budesonide suspension are very common treatments, and the effect is very fast and effective.

About the micromesh nebulizer

Micromesh nebulizer

Micromesh nebulizer: The working principle is to connect a perforated plate to a transistor that can generate high-frequency vibrations, and produce an impact on the liquid to produce aerosol; another way is that the liquid is driven by a pulse current to force it through the mesh to produce aerosol.

The micromesh nebulizer produced by Feellife Health Inc. ,has the characteristics of both compression atomizers and ultrasonic nebulizers, and has made breakthroughs in its technology. The spray method is to use tiny ultrasonic vibrations and a mesh spray head structure to spray, and use electronic high-frequency oscillations (which are absolutely harmless to humans and animals) through the high-frequency resonance of the ceramic atomizer to break up the liquid water molecule structure and produce a naturally flowing water mist, forming ultra-fine particles of about 3 microns, achieving an efficient spray effect. It is a home medical nebulizer for all respiratory diseases, which is easy to carry and use anytime, anywhere.

About the micromesh atomizer

Respirable range

0.5 to 5 microns

Aerosol particles larger than 5 microns settle in the mouth and throat and are swallowed

Particles smaller than 0.5 microns do not settle in the lungs and are exhaled

Respirable particle fraction

The percentage of particles smaller than 5 microns in aerosol

The higher the value, the better

The standards of medical institutions recommend that drugs contain at least 50% particles smaller than 5 microns (i.e., the mass median diameter is 5 microns or less)

About the micromesh atomizer

►Micro-mesh nebulizers are completely different from compressed nebulizers and are a revolutionary change in nebulization treatment equipment.

►Using high-frequency electronic oscillations (absolutely harmless to humans and animals), through the high-frequency resonance of ceramic nebulizers, the drug solution is driven to the mesh. Due to the extremely fast movement of positive and negative electrons, high-density atomized particles are produced and ejected outward.

►Since the Raffles micro-mesh atomizer has a 3-micron diameter screen at the nozzle, the sprayed liquid particles are all atomized particles with a diameter of less than 5 microns, of which 2.5-micron particles account for 75%.

Nebulizing inhalation inhalation combined with non-invasive ventilation therapy in COPD

Nebulizing inhalation combined with non-invasive ventilation therapy in COPD patients with respiratory failure and nursing. XU Xiao-ya,JIANG Mei-fang,WANG Yong-sheng,et al. China Aviation Industry 363 Hospital,Chengdu,Sichuan 610041,China

【Abstract】 Objective To explore the application and nursing of oxygen-driven inhalation joint with non-invasive ventilation therapy in COPD patients with respiratory failure. 

Nebulizing inhalation inhalation combined with non-invasive ventilation therapy in COPD

Methods 39 cases diagnosed COPD with respiratory failure during January 2011 to December 2012 in our department were randomly divided into two groups: the experimental group( 21 cases) and control group( 18cases) . The eperimental group useing non-invasive ventilation combined oxygen-driven inhalation otherwise the control group using conventional inhalation therapy ( off-hook inhalation) . Compare the improving of hypoxiacarbon dioxide retentiondyspneadifficulty in expectorationdry mouth and sore throat caused by noninvasive ventilation and improveing of lung function. Results Lung function and blood gas analysis results were all improved in Two groups after treatment. In addition to 1 cases in observation group was send to ICU due to exacerbationother cases were successfully weaned from non-invasive ventilator. The length of stay and ventilation time in experimental group were significantly lower than the control group. The ratio of sore throadry mouth and difficulty in expectoration in experimental group was statistically significante lower than the control groupP<0. 05. 

Nebulizing inhalation inhalation combined with non-invasive ventilation therapy in COPD

Conclusion Oxygen-driven inhalation therapy can improve the therapeutic effect and quality of life in COPD patients with respiratory failure using non-invasive ventilation during hospitalization and worthy of clinical application.